Ann: Positive Results Highlighted at ASPS Annual Meeting-AXP.AX, page-16

Hey Gareth

Question then is - will the saline expanders drop their price? will Aeroform lobby for higher price? - Market forces etc.

I don't think market forces will play a role at all. Admittedly, I'm not sure what a surgical consult for saline injection is, but I'm guessing patients are paying for time rather than a salt water injection. The benefits of Aeroform make saline expanders uncompetitive and redundant on two levels. Aeroform removes the need for surgeon consults weekly (up to 8 weeks) so firstly, surgeons will save time having to inject saline into breast tissue (which we all know is uncomfortable for patients - surgeons can utilise their time better too), and secondly, Medicare or insurers will avoid having to pay for each weekly consult, which could end up getting close to the price for Aeroform.

The fact the clinical report has 98% satisfaction is great - but of course it's sponsored by the company

Of course you can't rule out company bias, but you also can't fudge RCT results which showed time to expansion, Aeroform = 20 days, Saline Injection = 48 days. You can also apply logic  (like Pardner mentioned) - would you rather receive a jab weekly for 8 weeks, or take control over your own tissue expansion non-invasively? It also won best abstract, so obviously the congress they presented at had no issues with potential conflict of interest? Additionally, if you look closer at the disclosures of the authors, the bulk of them are from LifeCell and Allergan. Interestingly,  LifeCell appear to be the guys who supply tissue expanders for saline filling. I would say that negates any potential bias there.